A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma.

Gressin, Rémy; Daguindau, Nicolas; Tempescul, Adrian; Moreau, Anne; Carras, Sylvain; Tchernonog, Emmanuelle; Schmitt, Anna; Houot, Roch; Dartigeas, Caroline; Pignon, Jean Michel; Corm, Selim; Banos, Anne; Mounier, Christiane; Dupuis, Jehan; Macro, Margaret; Fleury, Joel; Jardin, Fabrice; Sarkozy, Clementine; Damaj, Gandi; Feugier, Pierre; Fornecker, Luc Matthieu; Chabrot, Cecile; Dorveaux, Veronique; Bouabdallah, Krimo; Amorin, Sandy; Garidi, Reda; Voillat, Laurent; Joly, Bertrand; Solal Celigny, Philippe; Morineau, Nadine; Moles, Marie Pierre; Zerazhi, Hacene; Fontan, Jean; Arkam, Yazid; Alexis, Magda; Delwail, Vincent; Vilque, Jean Pierre; Ysebaert, Loic; Le Gouill, Steven; Callanan, Mary B.
Haematologica; 2018 Aug 31.
Artigo em Inglês | MEDLINE | ID: mdl-30171024

Não foram localizados documentos relacionados